Aura Biosciences: Wall Street Sees 250% Upside Despite Prolonged Share Price Weakness

While Aura Biosciences shares have been mired in a months-long downtrend, market analysts maintain strikingly optimistic price targets for the biotech firm. A modest rebound occurred recently, but questions remain about whether this signals the beginning of a sustained recovery.

Substantial Cash Reserves Provide Operational Runway

Despite posting a quarterly loss of $27 million, Aura Biosciences possesses a solid financial foundation. The company holds $177.3 million in cash and marketable securities, which provides sufficient funding to operate through at least the first half of 2027. This financial cushion grants the necessary time to achieve critical clinical development milestones without immediate pressure.

Clinical Pipeline Anchored by Promising Candidate Bel-sar

The core of analyst optimism centers on the company’s developmental drug candidate, Bel-sar (AU-011). This therapy is currently undergoing a global Phase 3 trial named “CoMpass,” targeting the treatment of early-stage choroidal melanoma, a severe form of eye cancer. Patient recruitment for this pivotal study is projected to conclude by late 2025. Concurrently, a Phase 1b/2 study is evaluating Bel-sar for bladder cancer, with initial efficacy data anticipated before the end of this year.

Should investors sell immediately? Or is it worth buying Aura Biosciences?

Persistent Analyst Confidence Contrasts with Market Performance

Eight Wall Street analysts continue to recommend the stock as a “Buy” or “Strong Buy.” Their average price target of $22 implies a potential upside of nearly 250% from current trading levels. This bullish outlook is directly tied to the promise of the company’s clinical programs.

However, the stock’s technical performance tells a different story. The equity continues to trade significantly below its key moving averages and has declined more than 24% since the start of the year. Although the stock advanced over 5% in a recent session, potentially indicating a bottom formation, any meaningful and sustained reversal is widely expected to be contingent on positive forthcoming clinical data readouts.